线粒体内的核酸内切酶FEN1在非凋亡免疫细胞中响应各种PAMP刺激剪切Ox-mtDNA, 随后这些Ox-mtDNA片段穿过线粒体内膜的通透性转换孔(mitochondrial permeability transition pore, MPTP)和外膜的VDAC多聚体毛孔进入细胞质激活NLRP3炎性小体和cGAS-...
Author Correction: Differential binding of NLRP3 to non-oxidized and Ox-mtDNA mediates NLRP3 Inflammasome Activationdoi:10.1038/s42003-023-05019-2Cabral, AngelaCabral, Julia EliseWang, AngelinaZhang, YiyangLiang, HailinNikbakht, DonyaCorona, Leslie...
LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis. As a major receptor for oxidized low density lipoprotein (ox-LDL), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is upregulated in many p... Z Ding,S Liu,X Wang,... - 《Canadian ...
, mtDNA, mtROS, ATP, cardiolipin, N-formyl peptides) can activate innate immune receptors (e.g., FPR1, NLRP3, NLRC4 and TLR9) to promote inflammatory responses. In addition, a change in mitochondrial metabolism can induce monocyte differentiation into different types of macrophages: M1 (...
Post-glacial population history and genetic structure of the northern clingfish (Gobbiesox maeandricus), revealed from mtDNA analysis Mitochondrial d-loop sequences were analyzed to characterize the phylogeographic and population genetic structure of the northern clingfish (Gobbiesox maea......
6月16日,科望生物宣布其1类新药ES102注射液在中国申报临床并获受理,这是一款具有“first-in-class”设计理念的靶向激活OX40的六价抗体。OX40(又称CD134)是一类重要的T细胞共刺激分子,曾被人喻为继PD-1/L1之后的又一蓝海。据悉,全球已经有十余款OX40抗体迈入临床阶段,包括信达生物、辉瑞(Pfizer)、阿斯利康(Astra...
The accumulation of misfolded proteins, encoded by genetic variants of functional genes leads to Endoplasmic Reticulum (ER) stress, which is a critical consequence in human disorders such as familial hypercholesterolemia, cardiovascular and hepatic disea
近日,百济神州产品管线迎来两项重要进展。一是其自主研发的1类新药OX40激动剂BGB-A445注射液,获得中国国家药品监督管理局药品审评中心(CDE)临床试验默示许可;二是其引进的IL-6抑制剂注射用司妥昔单抗(siltuximab),在中国的新药上市申请审评状态已更新为:待审批,这意味着该药有望近期在中国获批。此外,百济神州自...
(mtDNA)expression.Inaddition,oxLDLstimulationunderhigh-GluconditionsactivatedtheintrinsicapoptosispathwayinECs.TheseeffectswereabolishedbySalBthroughreductionsinmtROSandmtDNA.Furthermore,SalBinhibitedoxLDL-andhighGlu–inducedincreasesinfissionprotein(p-DRP1andFIS1)levels.OxLDLandhighGluactivatedtheROCK1pathway...
2月9日,中国国家药监局药品审评中心(CDE)官网公示,康宁杰瑞有两款1类新药获得临床试验默示许可。根据公开资料,这两款新药分别为:1)抗PD-L1/OX40双特异性抗体KN052注射液,拟开发用于治疗晚期实体瘤患者;2)重组人源化PD-L1/CTLA-4双特异性单域抗体Fc融合蛋白注射液(KN046),拟开发用于联合阿昔替尼治疗晚期非...